TPG Looking To Sell Canadian Drugmaker For $3B

Law360, Los Angeles (August 7, 2013, 8:12 PM EDT) -- Private equity firm TPG Capital LP is considering a sale of Aptalis Pharma Inc., a Montreal-based drugmaker focused on the treatment of gastrointestinal disorders, for more than $3 billion, according to a Wednesday report.

Over the past few months, TPG has been collaborating with JPMorgan Chase & Co. and Evercore Partners Inc. to find a buyer for the specialty drugmaker, Reuters reported.

Salix Pharmaceuticals Ltd. and Indian company Sun Pharmaceutical Industries Ltd. were reportedly among the potential buyers who passed on bidding after they considered buying...
To view the full article, register now.